Dainippon Sumotomo Unit To Offer $190 Million To Buy Elevation Pharma
This article was originally published in PharmAsia News
A Dainippon Sumitomo unit said it would offer up to $190 million to buy Elevation Pharmaceuticals and its nasal allergy aerosol.
You may also be interested in...
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Medical device regulations that were set in place by the US FDA in the 1990s are evolving with the emergence of digital-health products and their iterative nature, medtech consultant Jon Speer says. Check out his comment here.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?